Invitation from Chair

Dear Colleagues in Cancer Treatment Development,

On behalf of the AAADV leadership, I would like to invite you to attend the 13th annual Accelerating Anticancer Agent Development and Validation Workshop May 4-6, 2016.

By attending the AAADV Workshop and its related educational offerings, you will be able to connect with others in the cancer drug development arena as well as broaden your knowledge of the regulatory sciences and clinical and translational medicine.

This year marks the introduction of two new AAADV offerings, both specifically designed for early-career scientists and patient advocates. AAADV Scholars and AAADV Fundamentals both premier on Tuesday, May 3, the day prior to the start of the AAADV Workshop. Thanks to grants from our sponsors, we are able to offer a limited number of scholarships to academics and patient advocates interested in attending.

Those of us who organized the initial AAADV Workshop in 2004 had no idea where this venture would lead or whether it might actually expedite the cancer drug development timeline. We have now trained nearly 2,000 investigators through our intimate annual workshop featuring regulators, academics, industry investigators and patient advocates working on the frontlines of cancer treatment.

The AAADV Workshop has not only impacted the rate at which oncology drugs are brought to market, but patients afflicted with cancer have been able to appreciate significant advances in their care and survival rates.

There is a perception by some that it takes too long to get a drug to market and that the development and approvals systems are broken. The current process produces only one successful drug for every 20 that enter into clinical evaluation, often at a cost of more than $1 billion.

The U.S. Food and Drug Administration has worked tirelessly to streamline the process to enable more cancer treatments to reach more patients more quickly, while ensuring that clinical trials and the approval process ensure maximum safety and effectiveness of the treatments they approve for patients.

The AAADV Workshop offers you rare access to many of FDA’s best people and valuable insight into the approval process, as well as opportunities to learn from and network with leaders in the world of cancer treatment.

When a patient asks me directly why he or she can’t get access to some new anticancer treatment in the pipeline, I want to be able to say that we are working on tangible solutions as a team. I urge you to attend the AAADV Workshop and lend your knowledge and experience to this important team effort.

Thank you for your attendance and support of the AAADV. I look forward to seeing you in Bethesda.


H. Kim Lyerly, M.D.

George Barth Geller Professor of Research in Cancer
Professor of Surgery
Duke University